Search by Categories
- Insights
- Rare Disease
- Oncology
- Cell and Gene Therapy
- Medical Devices
- Consulting
- News & Analysis
-
Therapeutic Areas
Our expertise in the industry
Parkinson's disease is a neurodegenerative disorder that affects predominately dopamine-producing (“dopaminergic”) neurons in a specific area of the brain called substantia nigra. Parkinson's dise...
Hot on the heels, Aurinia launches its drug in the Lupus market after GSK Aurinia Pharmaceuticals has recently got the USFDA approval for its Lupkynis (voclosporin) in combination with a backgr...
Neurological disorders are the leading source of disability globally, and Parkinson's is the fastest-growing neurological condition. It could be due to several factors ranging from an increase in ...
NICE recommends Pfizer’s Vizimpro for treating NSCLC Not long ago, Pfizer’s Vizimpro (dacomitinib) a tyrosine kinase inhibitor (TKI), was approved as a first-line monotherapy treatment for adul...
Parkinson's Awareness Month April marks Parkinson's Awareness Month, is an occasion to spread awareness about Parkinson’s. Not the early signs as they are more than just any tremor! Parkinson’s...
Parkinson's Disease (PD) is a chronic and progressive movement disorder which primarily affects dopamine-producing (“dopaminergic”) neurons in a specific area of the brain called substantia nigra....
With the advent of new-age healthcare industry trends that are evident as of now, there...
Although COVID-19 continued to dominate headlines in 2021, pharmaceutical companies did...
The Biosimilars market is growing at a breakneck pace. The biosimilar market provides a...
Chimeric antigen receptor T-cell (CAR T) therapies are shown to have transformative pot...
There has been limited progress in the approval of novel agents in MDS. It has been a l...
Hear from our subject-matter experts and in-house KOL’s on Pharma and Healthcare market trends.
